NEWS
  • March 4, 2021 S1 Biopharma CEO Nick Sitchon to Participate in Maxim Group LLC Review of Late Stage Innovations in Women’s Health
  • December 1, 2019 Dose-Finding Study of Lorexys for Hypoactive Sexual Desire Disorder in Premenopausal Women
  • January 4, 2019 S1 Biopharma to Participate in Panel Discussion on Investment Opportunities in China Hosted by Duane Morris and the Chinese Biopharmaceutical Association
  • January 4, 2019 S1 Biopharma Announces Expanded Analysis of Phase 2a Data on Lorexys™ for Treatment of Hypoactive Sexual Desire Disorder Based on PGIC Scale to be Presented at 2019 ISSWSH/ISSM Joint Meeting
  • December 20, 2018 S1 Biopharma Granted Patents for Lorexys™ in Europe and Asia for Treatment of Hypoactive Sexual Desire Disorder
  • April 5, 2016 MedicalResearch.com | CEO Discusses Lorexys For Female Hypoactive Sexual Desire Disorder
  • February 19, 2016 Pharmaceutical Processing | In Development: HSDD Treatment for Women
  • February 19, 2016 PM360 | Will Lorexys Succeed Where Addyi Flopped?
  • December 8, 2015 S1 Biopharma and CKD Pharmaceuticals Announce Commercialization Agreement for Lorexys™ in South Korea for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Women
S1 Biopharma
  • COMPANY
    • ABOUT US
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • MEDICAL ADVISORY BOARD
  • PIPELINE
    • OREXA
    • LOREXYS
    • S1B-307
    • S1B-3006
  • A New Vision for addressing Sexual Wellness
    • SEXUAL DYSFUNCTION R&D
    • SCIENTIFIC PUBLICATIONS
    • PARTNERING
  • NEWSROOM
    • PRESS RELEASES
    • MEDIA COVERAGE
  • INVESTORS
    • LOGIN
  • CONTACT US

S1 Biopharma Supports FDA Advisory Committee’s Recommendation to Approve the First-Ever Treatment for Hypoactive Sexual Desire Disorder

NEW YORK, June 5, 2015 /PRNewswire/ — Yesterday’s FDA Advisory Committee recommendation for the approval of flibanserin was a landmark step for women’s health, addressing the important unmet medical need for women living with hypoactive sexual desire disorder, or HSDD.…

Read more ›

S1 Biopharma Doses First Patients in Phase 2a Clinical Trial of Lorexys in Premenopausal Women with HSDD

Activity of Lorexys Requires Precise Ratio of Active Components, Trazodone and Bupropion JERSEY CITY, N.J., July 29, 2013 — S1 Biopharma, Inc., a developer of first-in-class drugs for sexual dysfunction in women and men, today announced enrollment and dosing of premenopausal…

Read more ›

S1 Pharmaceuticals Announces IND Filing of SIP-104 (Lorexys) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

60-Patient National Phase I-b Clinical Trial to Begin in 2012 Jersey City, NJ — February 20, 2012 — S1 Pharmaceuticals, Inc. (S1) announced today that it has submitted its Investigational New Drug (IND) application to the U.S. Food and Drug…

Read more ›


  • CONTACT US
  • SITE MAP
  • Terms of Use
  • © S1 biopharma Inc.
S1 Biopharma, Inc.
7 World Trade Center
250 Greenwich St.
46th Floor
New York City, NY 10007
Email: info@s1biopharma.com